Evolus, Inc. $EOLS Shares Sold by Boothbay Fund Management LLC

Boothbay Fund Management LLC decreased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 12.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,029,701 shares of the company’s stock after selling 141,392 shares during the quarter. Boothbay Fund Management LLC owned approximately 1.59% of Evolus worth $6,322,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in EOLS. Frazier Life Sciences Management L.P. bought a new position in shares of Evolus during the second quarter worth about $22,431,000. Soleus Capital Management L.P. boosted its stake in Evolus by 96.4% in the second quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after acquiring an additional 1,039,842 shares during the period. Caligan Partners LP boosted its position in Evolus by 23.8% during the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock valued at $25,413,000 after purchasing an additional 796,973 shares during the period. First Light Asset Management LLC bought a new position in shares of Evolus during the second quarter worth about $4,795,000. Finally, Frontier Capital Management Co. LLC grew its position in Evolus by 37.9% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock worth $15,333,000 after purchasing an additional 457,533 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

EOLS has been the subject of several recent analyst reports. Stifel Nicolaus decreased their price target on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, March 4th. Mizuho set a $15.00 price objective on shares of Evolus in a research note on Wednesday, February 4th. Needham & Company LLC restated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Finally, Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a research note on Sunday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Evolus Stock Performance

Evolus stock opened at $5.01 on Monday. Evolus, Inc. has a twelve month low of $4.09 and a twelve month high of $13.66. The firm has a market cap of $325.95 million, a PE ratio of -6.19 and a beta of 1.02. The firm’s 50 day moving average price is $4.89 and its two-hundred day moving average price is $6.13.

Evolus (NASDAQ:EOLS) last issued its earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million for the quarter, compared to the consensus estimate of $89.58 million. Equities analysts anticipate that Evolus, Inc. will post -0.61 EPS for the current fiscal year.

Insider Activity

In related news, insider David Moatazedi sold 10,539 shares of Evolus stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. This trade represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.